Cantor Fitzgerald Comments on SI-BONE FY2026 Earnings

SI-BONE, Inc. (NASDAQ:SIBN - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for SI-BONE in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn expects that the company will earn ($0.10) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for SI-BONE's current full-year earnings is ($0.78) per share.

Several other equities research analysts also recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and issued a $24.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th. Truist Financial lifted their price objective on shares of SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th.

SI-BONE Price Performance

SIBN stock traded down $0.39 during mid-day trading on Wednesday, hitting $18.42. The company had a trading volume of 91,269 shares, compared to its average volume of 382,472. The company has a 50-day moving average price of $16.41 and a 200 day moving average price of $15.65. SI-BONE has a 12-month low of $11.70 and a 12-month high of $20.05. The company has a market capitalization of $784.97 million, a price-to-earnings ratio of -20.02 and a beta of 0.94. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The firm had revenue of $47.29 million during the quarter, compared to analyst estimates of $45.13 million.

Insider Transactions at SI-BONE

In other news, Director Jeffrey W. Dunn sold 3,377 shares of SI-BONE stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $19.05, for a total value of $64,331.85. Following the transaction, the director now owns 17,354 shares of the company's stock, valued at $330,593.70. The trade was a 16.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the transaction, the senior vice president now owns 244,878 shares in the company, valued at approximately $3,462,574.92. This trade represents a 1.26% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 95,942 shares of company stock valued at $1,734,203. 4.00% of the stock is currently owned by corporate insiders.

Institutional Trading of SI-BONE

A number of hedge funds have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd purchased a new stake in shares of SI-BONE during the 1st quarter worth about $34,000. Virtus Fund Advisers LLC acquired a new stake in SI-BONE in the fourth quarter valued at approximately $40,000. Mainstream Capital Management LLC purchased a new stake in shares of SI-BONE in the fourth quarter valued at approximately $53,000. GAMMA Investing LLC raised its stake in shares of SI-BONE by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock worth $55,000 after buying an additional 3,867 shares during the period. Finally, Virtus Advisers LLC purchased a new position in shares of SI-BONE during the 1st quarter valued at approximately $58,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.